Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma
NK cells complexed with a CD30/CD16A bispecific antibody may help patients with advanced lymphoma
NK cells complexed with a CD30/CD16A bispecific antibody may help patients with advanced lymphoma
Two-year follow up of the CodeBreaK100 clinical trial demonstrated prolonged tumor responses and a favorable safety profile
Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment
AACR President David A. Tuveson will chair the symposium titled: Aging, Stress, and Cancer.
AACR President David A. Tuveson says clinicians will be ready and waiting before the cancer appears in the future
Researchers have found that a third COVID-19 vaccine increases vaccine effectiveness
A new era in sample processing and characterization
SelectScience editors will be reporting the latest news from this year’s AACR annual meeting. Detailed here, are some of the key things to look out for